Bayer is improving people’s quality of life by preventing, alleviating and curing diseases. In 2016 we invested a total of €4.4 billion in research and development. This figure represents a sound platform to introduce further innovative products in expanding life science markets.
Bayer holds a worldwide leading position in its main therapeutic areas and our Pharmaceuticals portfolio focuses on:
General Medicine & Specialty Medicine - General Medicines consists of prescription products, especially for cardiology and women’s health, whilst Specialty Medicines covers the areas of haematology, neurology, oncology and ophthalmology.